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The storage of triglyceride (TG) droplets in nonadipose tissues is called ectopic fat storage. Ectopic fat is associated with insulin
resistance and type 2 diabetes mellitus (T2DM). Not the triglycerides per se but the accumulation of intermediates of lipid
metabolism in organs, such as the liver, skeletal muscle, and heart seem to disrupt metabolic processes and impair organ
function. We describe the mechanisms of ectopic fat depositions in the liver, skeletal muscle, and in and around the heart and
the consequences for each organs function. In addition, we systematically reviewed the literature for the eﬀects of diet-induced
weight loss and exercise on ectopic fat depositions.
1. Introduction
The amount of people with obesity has increased dramati-
cally over the past decades to an estimated number of 400
million adults worldwide with a projected 700 million in
2015 [1]. Obesity predisposes to the development of insulin
resistance, type 2 diabetes mellitus (T2DM), and cardiovas-
cular disease (CVD) [2–7]. However, about 30% of obese
men and women are metabolically healthy [8], that is, do not
have hypertension, dyslipidemia, or disturbances in glucose
metabolism. Vice versa, these metabolic abnormalities occur
in 20–30% of normal weight people.
Adipose tissue consists of adipocytes and the so-called
stromal-vascular fraction that encompasses blood vessels and
stroma with macrophages. Adipose tissue has the unique
capacity to store large amounts of energy in the form of
triglycerides (TG). For a long time, it has been presumed
that this was the only function of adipose tissue. However,
adipose tissue (i.e., adipocytes and the stromal vascular
fraction) acts as an endocrine organ by secreting various
hormones and cytokines (also referred to as adipokines)
with eﬀects on glucose and lipid metabolism and energy
homeostasis [9]. It now appears that in those obese subjects
that develop insulin resistance, adipose tissue dysfunction
plays a role. Adipose tissue dysfunction is characterized
among others by large adipocytes and secretion of adipokines
with a proinflammatory profile ultimately leading to (among
others) ectopic fat deposition [10]. Ectopic fat is defined
as storage of TG in tissues other than adipose tissue, that
normally contain only small amounts of fat, such as the
liver, skeletal muscle, heart, and pancreas. Ectopic fat can
interfere with cellular functions and hence organ function
and is associated with insulin resistance.
The aim of this paper is to discuss the pathophysiology of
adipose tissue dysfunction and ectopic fat deposition.Wewill
elaborate on the eﬀect of ectopic fat deposition on the cellular
level as well as on the organ level for those organs involved
in the insulin-resistant pathogenesis of T2DM (liver and
skeletal muscle cell) and on the heart (because of the strongly
increased risk for coronary heart disease in T2DM). Since
there is uncertainty to date as to whether pancreatic steatosis
is causally related to beta-cell dysfunction [11–13], and
because it is not subject of investigation in our own studies,
we will not discuss fat accumulation in the pancreas. Finally,
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because diet and exercise are the mainstays of therapy for
obesity and T2DM, we systematically reviewed the literature
for the eﬀect of diet and or exercise on diminishing ectopic
fat stores and restoring insulin sensitivity in obesity and
T2DM.
2. Methods Systematic Review
The following databases were searched: PubMed (1949 to
January 2012), EMBASE (OVID-version, 1980 to January
2012), Web of Science (1945 to January 2012), and Cochrane
Library (1990 to January 2012). The search strategy consisted
of the AND combination of three main concepts:
(1) type 2 diabetes mellitus, Obesity, or insulin resis-
tance;
(2) weight loss, diet, or exercise;
(3) ectopic fat.
For these three concepts, all relevant keyword variations
were used. References were limited to human studies, adults,
written in English or Dutch. In addition, only studies
that used techniques that can quantify the amount of
lipid accumulation and measured insulin sensitivity were
included. Studies using surrogate markers for lipid accu-
mulation (e.g., alanine aminotransferase (ALT) or aspartate
aminotransferase (AST) as a proxy for hepatic steatosis)
were excluded. Hypocaloric diets are defined as containing
less calories than required for energy demands and usually
contain 1000–1200 kcal/day. Very low-calorie diets (VLCDs)
typically contain less than 800 kcal/day. See the appendix for
literature search details.
3. Adipose Tissue Dysfunction
The cause for adipose tissue dysfunction and ectopic fat
storage is largely unknown. Blu¨her [10] recently proposed
a model in which genetic, environmental, and behavioral
factors are involved in excess energy intake and decreased
physical activity on one hand as well as physiologic versus
pathologic fat accumulation on the other hand. The physio-
logic response to excess energy intake and less expenditure
would be an increase in fat cell number as well as fat cell
size (hyperplasia of adipose tissue) in the subcutaneous
compartment. These fat cells would function normally and
be insulin sensitive. On the contrary, a pathophysiologic
response would be adipocyte hypertrophy.
Human adipocytes can grow up to ∼20 fold in diameter
and several thousand-fold in volume [14]. However, when
adipocytes become too large, stress signals will be released.
For example, hypoxia can occur when vascularisation is
inadequate for the expanded adipose tissue. In addition,
endoplasmatic reticulum (ER) stress [15], either induced
by hypoxia or nutrient excess, leads to an unfolded protein
response (UPR) [16]. In the ER, proteins are translated,
folded, and assessed for quality before release. With ER stress
the number of misfolded proteins increases and triggers
the UPR. The UPR induces genes involved in assembling,
folding, modifying, and degrading proteins to alleviate ER
stress and triggers the activation of stress and inflammatory
pathways and the production of cytokines and chemokines
that interfere with the insulin signaling pathway.
Dysfunctional adipocytes produce more inflammatory
adipokines and cytokines than functional adipocytes. In
addition, stressed adipocytes attract immune cells (among
which macrophages) into the stromal vascular fraction. The
physiological role of infiltrating macrophages is probably
debris clearing (ER stress can eventually lead to premature
adipocyte apoptosis). Eventually however, a positive feedback
cycle is formed in which infiltrating macrophages recruit
more immune cells, and a state of chronic inflammation is
induced. Some of the cytokines and adipokines produced
interfere with adipocyte diﬀerentiation, others with insulin
signaling. Some, like TNF-α and IL-6, impair adipocyte
diﬀerentiation, reduce lipid accumulation, and increase
adipocyte lipolysis.
The latter is on top of the poor ability of stressed and
hypertrophic adipocytes to take up and release free fatty
acids (FFAs). This induces a redirection of lipids towards
peripheral tissues, including skeletal muscle, liver, pancreas,
and heart: ectopic fat deposition.
If in these tissues, lipid supply exceeds oxidative capacity
intracellular lipid accumulation occurs, and organ function
might be impaired (Figure 1).
4. Cellular Mechanisms of Ectopic Fat-Induced
Organ Dysfunction
The consequences of ectopic fat accumulation depend on
the specific organ. However, the mechanisms leading to the
disruption of organ function are quite similar at the cellular
level (Figures 2(a)–2(c)).
Firstly, it has to be noted that lipids can be dis-
persed intercellularly or accumulate intracellularly. Intercel-
lular lipid accumulation might impair organ function via
paracrine eﬀects of the released adipokines. However, it
is intracellular lipid accumulation that is associated with
decreased insulin sensitivity.
Free fatty acids are taken up by the cell via specific trans-
port proteins in the cell membrane (CD36, fatty acid trans-
port protein (FATP), along with passive diﬀusional uptake
[17]. Inside the cell, fatty acid binding protein (FABPc) is
the most important cytosolic protein for guiding long-chain
fatty acids in the cell to places of oxidation or esterification.
Long-chain fatty acyl-CoA is taken up by the mitochondria
via carnitine-palmitoyl transferase 1 (CPT1). Inside the
mitochondria, β-oxidation and further degradation in the
tricarboxylic acid cycle takes place. Therefore, intracellular
lipid accumulation occurs as a consequence of continuous
oversupply of FFAs (caused by enhanced lipolysis, adipocyte
dysfunction) together with an impairment in FFA oxidation
in the mitochondria.
It appears that not the FFAs themselves but rather
metabolites like long-chain acyl-CoA (LC-CoA), diacylglyc-
erol (DAG), and ceramides are deleterious for the cell.
These fatty acid metabolites induce a sustained activation
of serine/threonine kinases such as protein kinase C (PKC)
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Figure 1: Ectopic fat depositions. Gene-environment interactions might be involved both in increased energy intake and decreased physical
activity as well as in the response of adipose tissue to the ensuing increased energy balanced. Predisposed subjects will elicit a pathophysiologic
response leading to adipocyte hypertrophy. This will lead to an inflammatory response that ultimately leads to ectopic fat deposition. The
consequences of ectopic fat are organ specific as depicted in this figure. The eﬀect of ectopic fat on the cellular level is diﬀerent and depicted
in Figure 2. FFAs: free fatty acids; EGP: endogenous glucose production; VLDL-TG: very low-density lipoprotein-triglyceride.
isoforms, IKB-kinase-β and Jun N-terminal kinase, which
phosphorylate insulin-receptor substrates (IRS) on serine
residues [18]. The subsequent defects in insulin signaling
lead to a decrease in cellular function that depends on the
cell type. Figure 2 describes the eﬀects of intracellular lipid
accumulation in skeletal muscle, liver, and cardiomyocytes
[18, 19]. The explanation for the various organs is described
in the following paragraphs and is the explanation of Figures
2(a) to 2(c).
FFAs are taken up by the skeletal muscle cell mainly
by protein-mediated membrane transport (CD36, fatty acid
transport protein (FATP)), along with passive diﬀusional
uptake. Long-chain fatty acyl-CoA is taken up by the
mitochondria via carnitine-palmitoyl transferase 1 (CPT1)
[17]. Inside the mitochondria β-oxidation and further
degradation in the tricarboxylic acid cycle takes place. When
there is an oversupply of FFAs and/or an impairment in
mitochondrial β-oxidation exist, LC-CoA accumulates and
is broken down to intermediates like DAG and ceramide.
These fatty acid metabolites induce a sustained activa-
tion of serine/threonine kinases such as protein kinase C
(PKC) isoforms, IKB-kinase-β and Jun N-terminal kinase,
which phosphorylate insulin-receptor substrate (IRS) 1 on
serine residues [18]. Serine-phosphorylated forms of IRS1
cannot associate with and activate phosphatidyl-inositol-
3-kinase (PI3K), resulting in a decreased glucose trans-
porter 4 (GLUT4) regulated glucose transport over the
cell membrane. FATP: fatty acid transport protein; FFA:
free fatty acid; LC-CoA: long-chain fatty acid-CoA; DAG:
diacylglycerol; PKC: protein kinase C; IR: insulin receptor;
IRS: insulin receptor substrate; PI3K: phosphatidylinositol
3-kinase; PKB/AKT: protein kinase B/AKT; GLUT4: glucose
transporter protein 4; GS: glycogen synthase.
The mechanism behind hepatic TG accumulation and
the development of hepatic insulin resistance are similar to
that described for skeletal muscle [18, 20]. An increase in
DAG in hepatic cells leads to activation of PKC, leading to
decreased insulin receptor kinase activity and subsequently
lower insulin-stimulated IRS2 tyrosine phosphorylation
and lower IRS2-associated PI3K-activity which results in
reduced insulin stimulation of glycogen synthase activity.
This ultimately leads to decreased insulin-stimulated hepatic
glucose uptake and reduced insulin suppressibility of hepatic
glucose production. Furthermore, reduced activity of AKT2,
a protein kinase downstream of IRS and PI3K, results in
decreased phosphorylation of the forkhead box O (FOXO)
transcription factor, allowing it to enter the nucleus and
activate the transcription of the rate-controlling enzymes
of gluconeogenesis. The result is increased hepatic glucose
production and decreased hepatic glucose uptake, which
both contribute to increased plasma glucose levels. FATP:
fatty acid transport protein; FFA: free fatty acid; LC-
CoA: long-chain fatty acid-CoA; DAG: diacylglycerol; PKC:
protein kinase C; IR: insulin receptor; IRS: insulin recep-
tor substrate; PI3K: phosphatidylinositol 3-kinase; GSK3:
glycogen synthase kinase 3; FOXO: forkhead box protein O;
GLUT2: glucose transporter protein 2.
In the heart, increased FFA supply and decreased
oxidation lead to lipid intermediates that impair insulin
signaling, and hence GLUT-4 involved glucose uptake. In
addition, lipid-induced PKC activation might be involved
in premature adipocyte apoptosis and heart failure. Finally,
accumulation of lipids increase DAG and ceramide levels
inducing a vicious cycle in which a further impairment
in mitochondrial fatty acid oxidation occurs that also has
negative eﬀects on myocardial function. FATP: fatty acid
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Figure 2: (a) cellular processes leading to insulin resistance in the skeletal muscle cell; (b) cellular processes leading to insulin resistance in
the liver cell; (c) cellular processes in the cardiomyocyte leading to myocardial dysfunction.
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transport protein; FFA: free fatty acid; LC-CoA: long-chain
fatty acid-CoA; DAG: diacylglycerol; PKC: protein kinase C;
IR: insulin receptor; IRS: insulin receptor substrate; PI3K:
phosphatidylinositol 3-kinase; GLUT4: glucose transporter
protein 4.
5. Skeletal Muscle
5.1. Intramyocellular Lipids and Peripheral Insulin Resistance.
Accumulation of intramyocellular lipids (IMCLs) as mea-
sured by skeletal muscle biopsies or 1H-magnetic resonance
spectroscopy is associated with insulin resistance [21–26]
and T2DM. However, it is not synonymous with the
condition given the fact that endurance-trained athletes, who
are highly insulin sensitive, also have a high IMCLs content
[26]. Rather, the capacity to oxidize IMCLs determines
whether they represent a physiological or a pathological
role [27]. In endurance-trained athletes IMCLs are an
adaptive response, the IMCLs serve as a readily available
energy source. The close proximity of lipid droplets to the
mitochondria supports this hypothesis. In these athletes,
IMCLs are not deleterious because of the increased capacity
to oxidize lipids. In insulin-resistant and/or T2DM patients,
the increased IMCLs stores are the result of increased FFA
availability and impaired fatty acid oxidation [28–30]. The
latter leads to accumulation of lipid intermediates with the
ascribed toxic eﬀects on insulin signaling (Figure 2). Hence,
the ratio between IMCLs and fat oxidative capacity is a better
marker for insulin resistance than IMCLs alone.
The fact that fatty acid oxidation is impaired in insulin-
resistant states led to the speculation that mitochondrial
dysfunction is the cause of IMCLs accumulation and the
ensuing insulin resistance. Indeed, a decreased mitochon-
drial density and/or function has been reported in insulin-
resistant oﬀspring of T2DM patients [31–33] and T2DM
patients [34–37]. However, three of these studies reported
decreased mitochondrial function at normal IMCLs levels
[35–37] suggesting that impaired mitochondrial function
is not a prerequisite for IMCLs accumulation. Rather, it
might be that mitochondrial dysfunction is the consequence
of the increased amount of fatty acid metabolites, for
example, via the formation of lipid peroxides [38]. In
that case it might be that the lipid-induced mitochondrial
dysfunction induces progressive deterioration of oxidative
capacity and further accumulation of lipid intermediates
in the skeletal muscle cell. Further investigations are war-
ranted to elucidate which one is cause or consequence:
IMCLs or mitochondrial dysfunction. In this paper, we
focus on IMCLs and will not elaborate on mitochondrial
function.
5.2. Eﬀect of Diets on IMCLs Accumulation (Table 1). When
assessing the eﬀects of diet on insulin sensitivity and IMCLs
content both severity of the caloric restriction, duration of
the intervention, amount of weight loss and perhaps severity
of insulin resistance and duration of T2DM have to be
taken into account. From the available literature (Table 1),
it is diﬃcult to draw definite conclusions as to which of
these parameters has the greatest eﬀect on improving insulin
sensitivity and IMCLs [39–45].
For example, moderate weight reduction (3–11 kg) with
hypocaloric diets showed no eﬀect on insulin sensitivity or
on IMCLs content in normal glucose tolerant (NGT) obese
subjects [39, 42, 44–46] or T2DM patients [41, 43] in 3
studies. However, a recent study did show an increase in
insulin-stimulated glucose disposal along with a decrease
in IMCLs content following around 8 kg weight reduction
with a hypocaloric diet (−500 to –40 kcal/day based on
food diaries) in elderly obese subjects with impaired fasting
glucose or impaired glucose tolerance [47]. Maybe the low
fat content of the diet accounts for the observed diﬀerence as
compared to the other 3 studies. Alternatively, the pathogen-
esis of impaired glucose metabolism (and hence its reversal)
might be diﬀerent in older as compared to younger subjects.
The amount of caloric restriction seems to be important
since moderate weight reduction with a low-calorie diet [45]
or a very low-calorie diet [48] significantly improved insulin
sensitivity although it had no eﬀect on IMCLs in obese
NGT subject. One study using a VLCD showed not only
an improvement in insulin sensitivity but also a decrease in
IMCLs, even after 6 days of the VLCD, in obese and T2DM
patients [49]. It should be noted; however, that IMCLs were
measured in soleus muscle with 1H-MRS, whereas other
studies mostly measure IMCLs in the vastus lateralis muscle.
In addition, with respect to insulin sensitivity, very high
doses of insulin (200mU/m2/min) were used.
Pronounced weight loss (∼22 kg) using a VLCD
(450 kcal/day, on average 17 weeks duration) in obese
insulin-treated T2DM patients not only improves peripheral
insulin sensitivity but also decreases IMCLs in skeletal muscle
biopsies [50] (Table 1).
5.3. Eﬀect of Diet and Exercise on IMCLs Accumulation.
Several studies investigated the eﬀect of the addition of
exercise to a hypocaloric or VLCD in obese NGT or obese
T2DM patients (Table 1). All studies in obese NGT [45,
51, 53], obese impaired glucose tolerant (IGT) [54], or
obese T2DM patients [43, 52] consistently showed increased
insulin sensitivity with no diﬀerences between diet-only or
diet with exercise group (with the exception of [45] all
measured with the hyperinsulinaemic euglycaemic clamps).
The eﬀect of adding exercise on IMCLs in these studies
was less consistent showing either no eﬀect [45, 51, 53],
a decrease [43, 54], or even an increase [52] in IMCLs
accumulation.
5.4. Eﬀect of Exercise on IMCLs Accumulation. Few studies
have addressed the eﬀect of exercise only on IMCLs and
insulin sensitivity. Three studies on obese NGT [55] and
obese IGT subjects [47, 54] showed an increase in insulin-
stimulated glucose disposal despite minimal weight loss (1–
3 kg). Two of those studies [47, 55] showed an increase in
IMCLs with a decrease in intramuscular ceramide and DAG
levels along with increased lipid oxidation rates. The other
study showed a decline in IMCLs both in the diet + exercise
as well as in the exercise-only group [54].
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In 18 T2DM patients (body mass index (BMI) 30 kg/m2,
HbA1c 7.2%, age 59 years) a 12-week combined aerobic and
resistance program had no eﬀect on body weight [56] but
improved insulin-stimulated glucose disposal and increased
IMCLs along with an increase in insulin-stimulated glucose
oxidation and suppression of fat oxidation (Table 1). Inter-
estingly, the same intervention had no eﬀect on peripheral
insulin sensitivity and IMCLs in healthy-matched controls.
5.5. Conclusion. Moderate weight loss has no eﬀect on
IMCLs but can improve peripheral insulin sensitivity if a
VLCD is used. Larger weight losses are needed to improve
both peripheral insulin sensitivity and deplete IMCLs stores.
With respect to the eﬀect of exercise on IMCLs, the story
is more complex. Athletes have increased IMCLs stores
that serve as a readily available energy supply and training
further increases IMCLs in healthy subjects. On the other
hand, sedentary insulin-resistant subjects also have increased
IMCLs, caused by diminished oxidative capacity. These are
associated with increased intramyocellular lipid intermedi-
ates that interfere with insulin signaling and other cellular
processes. Exercise training in these subjects either increases,
decreases, or has no eﬀect on IMCLs accumulation. This
is probably associated with the stage of disease (can fatty
acid oxidation and/or mitochondrial function be restored)
as well as with the intensity of the exercise program
and sort (aerobic/resistance) exercise. Overall, studies show
that exercise improves peripheral insulin sensitivity. Factors
involved are a reduction in lipid intermediates and hence
improved insulin signaling and mitochondrial function,
increased oxidative capacity and increased capillary blood
flow. In addition, contraction and hypoxia activate adenosine
monophosphate-activated protein kinase (AMPK) which
leads to increased GLUT4 translocation independent of
insulin.
6. Liver
6.1. Intrahepatic Lipids and Insulin Resistance of the Liver.
Accumulation of fat in the liver in the absence of excessive
alcohol ingestion is referred to as nonalcoholic fatty liver
disease (NAFLD). The spectrum of liver abnormalities
within this entity ranges from hepatic steatosis with or
without mild increases in serum AST/ALT to nonalcoholic
steatohepatitis (NASH) with or without fibrosis, cirrhosis,
and incidental hepatocellular carcinoma. The worldwide
estimated prevalence of NAFLD in the general population
is about 20%, with large diﬀerences across countries [57].
There is a strong positive correlation between NAFLD and
obesity. A cross-sectional study on 1515 severely obese NGT
subjects showed some signs of fatty liver changes in almost
90% of people [58]. The majority had hepatic steatosis,
but one-third had portal inflammation and fibrosis. A
prospective study demonstrated a 4-time increased risk to
develop hepatic steatosis in obese persons as compared to
controls [59].
Noninvasive methods for measuring hepatic TG content
such as ultrasound, CT, and 1H-MRS cannot distinguish
NAFLD from NASH and fibrosis. A definite diagnosis can
only be made by liver biopsy with histologic examination.
The cutoﬀ value for abnormal lipid accumulation in the liver
has been defined as more than 5% of liver volume or when
more than 5% of hepatocytes contain visible intracellular
lipids [60]. Two recent studies in respectively a NGT mixed
(Hispanic, non-Hispanic, and African American) population
[61] and a lean Caucasian population [62] found that the
95th percentile for hepatic TG content was 5.6% and 3%,
respectively, using 1H-MRS. The Pathology Committee of
the NASH Clinical Research Network designed and validated
a scoring system of 14 histological features examining liver
biopsy findings detailing steatosis, fibrosis, inflammation,
and liver cell injury [63]. An NAFLD activity score >5 was
universally associated with NASH.
Fat accumulation in the liver is associated with hepatic
insulin resistance as well as with peripheral insulin resis-
tance in skeletal muscle and adipose tissue [64–67]. In a
large European cohort of 1307 middle-aged NGT subjects,
patients with a high fatty liver index (an estimate for
hepatic steatosis based on an algorithm including BMI, waist
circumference, TG, and gamma-glutamyltransferase) had a
lower glucose disposal rate as measured by a euglycaemic
hyperinsulinaemic clamp as well as higher FFA levels at the
end of the insulin infusion [68]. The latter is suggestive for
decreased insulin sensitivity of adipose tissue. Korenblat et al.
[64] found a negative correlation between hepatic insulin
sensitivity measured by the hyperinsulinaemic euglycaemic
clamp and hepatic TG content (measured by 1H-MRS) in
42 nondiabetic obese subjects. Indeed, a multivariate linear
regression analysis found that hepatic TG content was the
best predictor of insulin sensitivity in liver, skeletal muscle,
and adipose tissue, independent of BMI and percent body
fat. Some claim that the amount of hepatic TG content is
directly correlated with the severity of insulin resistance, but
this cannot be confirmed by others.
6.2. Eﬀect of Diet on Intrahepatic Lipids. Noninvasive tech-
niques like CT and 1H-MRS have shown that weight loss
by nutritional interventions can result in a large decrease in
hepatic TG content in obese and T2DM subjects [41–43, 69–
73]. Because of the diﬀerent populations and diﬀerences in
baseline hepatic TG content, studies are not well comparable
with respect to the individual eﬀect of level of caloric
restriction and/or amount of weight reduction on loss of
hepatic TG content. Nonetheless, it has been shown that
even a relatively small drop in BMI of 3–6% is associated
with a considerable reduction in hepatic TG content of
34–40% [42, 70, 71]. The main reduction in hepatic TG
content already occurs in the first two weeks of dietary
restriction [43, 69]. The percentual decline in hepatic TG
content positively correlates with the hepatic TG content
at baseline, as patients with a high hepatic TG content
at start of the diet lose relatively more TG than patients
with low hepatic TG content, with the same amount of
weight loss [70, 72]. Only two studies measured both
hepatic TG content and hepatic insulin sensitivity with a
hyperinsulinaemic euglycaemic clamp in obese NGT [73]
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and obese T2DM patients, respectively [41]. Both studies
found an improvement in hepatic insulin sensitivity that was
associated with the decrease in intrahepatic lipids (IHL).
Although the above-mentioned studies clearly show that
diet-induced weight loss leads to a decrease in hepatic TG
content, the eﬀect of this decrease in hepatic TG content on
liver histology (i.e., with liver biopsies) has only been scarcely
studied. In obese patients with NASH moderate weight loss
over a 12-month period, obtained with dietary advices only,
led to an improved steatosis score in 9 of the 15 subjects.
The improvement was associated with greater weight loss as
compared to the patients that showed no change in steatosis
[74]. Another study on 15 patients with obesity and NASH
combined a hypocaloric diet with exercise during 12 weeks,
while 10 obese subjects with NASH served as controls. The
BMI decreased by 3 kg/m2 in the intervention group, and the
steatosis score decreased from 2.3 to 1.3 (30–50% steatosis
to less than 30%), while no changes were observed in the
control group [75]. In contrast, severe caloric restriction
during 8 months in 41 morbidly obese (BMI 43.3 kg/m2)
subjects leading to an impressive median weight loss of 34 kg
(−27% of BMI) showed normalization of liver architecture
in 19 patients [76]. However, they also found an increase in
hepatic inflammation and fibrosis in some patients, this was
associated with a greater weight loss and elevated FFAs.
6.3. Eﬀect of Diet and Exercise on Intrahepatic Lipids. Most
studies combine an exercise program with a hypocaloric diet.
Since short-term diet alone already reduces IHL, it is diﬃcult
to extrapolate whether adding exercise has additional eﬀects
[77, 78]. Both in obese as well as in T2DMpatients combined
diet with exercise interventions led to a reduction of hepatic
steatosis. Larson-Meyer studied a diet-only (25% calorie
restriction (CR)) versus a diet (12.5% CR) combined with
exercise (12.5% CR) obese NGT group. In this 6-month
study no additional eﬀect of exercise upon the diet was found
at an equal total amount of caloric restriction [45]. Another
6-month study in older sedentary obese subjects also showed
no additional eﬀect of exercise on IHL content and insulin
sensitivity measured by oral glucose tolerance test (IHL diet:
−46 ± 11%, diet + exercise: −45 ± 8%; insulin sensitivity
diet: 66 ± 25%, diet + exercise: 68 ± 28%) [79].
6.4. Eﬀect of Exercise on Intrahepatic Lipids. Only one study
has investigated the influence of exercise alone on hepatic
TG content in adult overweight (BMI 27.7 ± 0.5 kg/m2)
sedentary men [80] and simultaneously measured hepatic
insulin sensitivity with a state of the art technique. After a
6-week aerobic exercise program (60–85% of VO2max for a
minimum of 20min. at least three times per week) without
significant eﬀect on body weight no changes were found in
hepatic TG content as measured by 1H-MRS, although both
peripheral and hepatic insulin sensitivity (measured by the
hyperinsulinaemic euglycaemic clamp) improved.
This is in contrast with a study in obese NGT sub-
jects in which a one-month aerobic exercise training (3
times/week, 3–45/min at max 70%VO2max) decreased hep-
atic TG concentration by 21% at equal body weight. Hepatic
Figure 3: Four-chamber view of the heart. Four-chamber view of
the heart where the signal from blood and muscle are suppressed.
E: epicardial fat; P: pericardial fat.
insulin sensitivity was not measured, HOMA-IR remained
unchanged [81].
Perhaps the amount of IHL at start of the study and/or
the severity of the impairment in glucose metabolism
accounts for the observed diﬀerences.
Interestingly, in 196 overweight, sedentary dyslipidemic
subjects an 8-month exercise intervention showed that aero-
bic exercise is more eﬀective in reducing liver fat and insulin
sensitivity (measured by HOMA) than resistance training.
A combined resistance and aerobic exercise program was
as eﬀective as aerobic exercise on the above-mentioned
outcome parameters [82].
7. Epicardial and Pericardial Fat
Pericardial fat is the adipose tissue surrounding the heart. It
consists of two layers: epicardial fat (visceral fat) originating
from mesothelial cells and paracardial or mediastinal fat,
originating from mesenchymal cells [83] (Figure 3).
Around 80% of the heart is surrounded by epicardial fat
and epicardial fat makes out 20% of total heart weight. The
latter varies more among men than in women; 15.2–25.2%
and 19.5–21.7%, respectively. The largest part can be found
around the right ventricle followed by the anterior wall. The
amount of epicardial fat increases with age until age 20–40,
thereafter there is no age dependence [83, 84].
Several functions have been proposed for epicardial fat
tissue [84]. Scientific proof is, however, rather diﬃcult to
obtain since most animal species have very little epicardial
fat [85]. In guinea pigs, rates of lipolysis and lipogenesis
were 2 fold higher in epicardial fat than in other fat depots.
This led to the assumption that epicardial fat might act as
a buﬀer to protect the myocardium from highly toxic fatty
acid levels and to provide fatty acids as a direct energy source
in times of energy demand [85, 86]. Coronary arteries are
embedded in epicardial fat so that another putative function
might be to protect the coronary arteries from the tension
and torsion induced by the arterial pulse wave and provide
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an environment in which the coronary arteries can easily
expand. This fat compartment also acts as a metabolically
active organ, secreting cytokines [87, 88].
Several cross-sectional studies have suggested a positive
relation between an increased epicardial fat volume and
coronary artery disease [89–92]. Furthermore, an increased
epicardial fat volume has been associated with insulin
resistance in nondiabetic obese patients [93] and with the
presence of T2DM in a Han Chinese population [94, 95].
Therefore, it is interesting to study the eﬀects of weight loss
and diet on epicardial fat and insulin resistance.
7.1. Eﬀect of Diet on Epicardial Fat. Two studies have
examined the eﬀect of diet-induced weight loss on epicardial
fat. Kim et al. [96] studied 27 moderately obese NGT
subjects, who lost 11% (9.5 kg) of weight during a 12-
week weight loss intervention study. Epicardial fat thickness
measured over the right ventricle wall by echocardiography
decreased by 17% from baseline. Iacobellis et al. [97] studied
20 severely obese (BMI 45 ± 5 kg/m2) subjects (probably
including patients with IGT or T2DM) who followed
a 6-month low-calorie diet (900 kcal/day) and lost 20%
(25 ± 10 kg) of bodyweight. Epicardial fat decreased by 32%
from baseline. This was accompanied by an improvement
in left ventricular mass and diastolic cardiac function. The
change in diastolic function was also positively correlated
with the change in epicardial fat thickness. Moreover, in 15
obese patients with T2DM, we found a significant decrease
in pericardial fat after weight loss with a 16-week VLCD,
measured with MRI (accepted for publication in Obesity)
[98].
7.2. Eﬀect of Exercise on Epicardial Fat. To date, only two
studies examined the eﬀect of (aerobic) exercise on epicardial
fat [99, 100]. In one study, 24 obese NGT (BMI 30.7 ±
3.3 kg/m2) middle-aged Japanese men followed a supervised
exercise program for 3 months. The exercise intensity was
gradually increased in 4 weeks from 50–60 to 60–70% of
the maximum heart rate 3 days/week 60 minutes, which
was continued for the remainder of the study. Following
the intervention the BMI decreased by 4.3 ± 3.0% (circa
−1 kg/m2) and VO2max increased by 20%. Epicardial fat
thickness measured by echocardiography over the free wall
of the right ventricle decreased significantly. The change in
visceral adipose tissue (−15%) was significantly correlated
with the change in epicardial adipose tissue (−8.6%).
In the other study, 32 obese postmenopausal women
were randomized to diet-only or diet combined with mod-
erate or intensive exercise for 20 weeks. All three groups had
a similar 15% reduction in bodyweight and a 17% reduction
in pericardial fat. However, no diﬀerences were observed
between the diet-only and diet with exercise group [100].
8. Myocardial Triglyceride Content
In addition to the epicardial/pericardial fat depositions, TG
can also be stored within the cardiomyocytes. This is referred
to as myocardial TG content or myocardial steatosis. Myocar-
dial TG accumulation can be measured with great sensitivity
by 1H-MRS [101]. Patients with IGT and T2DM have an
increased myocardial TG content compared to obese and
lean controls [102–104]. This accumulation of myocardial
TG is a result of excessive fatty acid uptake relative to the
oxidation. If fatty acids are converted to myocardial TG,
several intermediates are released (e.g., ceramide) which in
animal models caused cardiac dysfunction [105, 106]. In
T2DM patients, myocardial steatosis was associated with
impaired left ventricular diastolic function [104]. Indeed,
an increased fatty acid uptake in the myocardium has been
found in healthy obese and T2DM patients compared to
healthy lean subjects [107, 108]. But in the one study that
investigated the fate of the intracellular fatty acids in the
resting state in insulin-naı¨ve T2DM patients as compared to
controls an increase, not a decrease in fatty acid oxidation
was found. Fatty acid reesterification was negligible but
lower in T2DM patients as compared to the controls [108].
Interestingly, neither plasma NEFA levels nor myocardial
blood flow was increased both in subjects with obesity
[107] and T2DM [108] suggesting another mechanism, for
example, at the (cellular) level of the FAT/CD36, to account
for the increased fatty acid uptake (Figure 2(c)).
The myocardial TG content is not static. Three days of
severe caloric restriction (450 kcal/day to complete starva-
tion) in healthy volunteers and patients with T2DM increases
myocardial TG content, which is associated with a decrease in
left ventricular diastolic function [109, 110].
8.1. Eﬀect of Diet on Myocardial Triglyceride Content. Thirty-
four obese (BMI 33.7 ± 0.7 kg/m2) healthy persons under-
went a 6-week VLCD (550 kcal/day). Before and after the
intervention intramyocardial TG were measured, a hyper-
insulinaemic euglycaemic clamp was performed and either
glucose uptake or fatty acid uptake was measured by positron
emission tomography. The intervention led to a weight loss
of 11.2 ± 0.6 kg and a nonsignificant decrease in myocardial
TG content of 31% (n = 8, P = 0.076).Myocardial fatty acid
uptake decreased significantly. Myocardial mass and work
decreased significantly by 7 and 26%, respectively [111].
Our group investigated the eﬀect of a 16-week VLCD
(450 kcal/day) on myocardial TG content in obese patients
with T2DM [112]. We showed that a decrease in BMI
(from 35.6 ± 1.2 to 27.5 ± 1.3 kg/m2) was associated with
a significant decrease in myocardial TG content and an
improvement in left ventricular diastolic function.
8.2. Eﬀect of Exercise on Myocardial Triglyceride Content.
In 14 NGT overweight-obese middle-aged men, a 12-week
training program (3 times per week, combined aerobic and
resistance training) reduced lipid accumulation at the cardiac
septum (0.99 ± 0.15 to 0.54 ± 0.04%, P = 0.02) and
improved left ventricular function slightly but significantly
[113].
In obese patients with T2DM, however, a comparable
12-week intervention had no eﬀect on cardiac lipid con-
tent measured in the septum, although both whole-body
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insulin sensitivity as well as left ventricular ejection fraction
improved [114].
Together these data suggest that a decrease in cardiac lipid
content is not a prerequisite for improved left ventricular
function. Several factors might explain this. Firstly, a similar
mechanism like with IMCLs in endurance-trained athletes
(have increased IMCLs but an increased fatty acid oxidative
capacity) might play a role. It would be, therefore, interesting
to study endurance-trained athletes to see whether they
have, like in skeletal muscle, higher levels of intramyocardial
TG than healthy controls and whether this is associated
with increased myocardial fatty acid oxidation and is related
with cardiac function. On the other hand, improved insulin
sensitivity with lower glucose and lipid levels might account
for the improvement in cardiac function in the above 2
studies. However, plasma lipid levels did not change in the
2 studies.
9. Discussion
T2DM is a multifactorial disease in which genetic, environ-
mental and lifestyle factors induce insulin resistance and
impaired insulin secretion, ultimately leading to chronic
hyperglycemia and its complications. Given the association
between T2DM and obesity the recent focus of research has
been the link between them. Vague already described a link
between visceral adipose tissue, insulin resistance and T2DM
in 1947 [115]. But it has not been until the start of the
obesity and diabetic epidemic that further elaboration on
his work started. This research revealed that adipose tissue
is not merely a storage depot for TG but actively secretes a
vast array of factors such as cytokines, metalloproteinases,
and adipokines that can induce inflammation and insulin
resistance [9].
In addition, with the advancement of radiological tech-
niques it has become apparent that patients with insulin
resistance and T2DM not only have a higher visceral to
subcutaneous fat ratio as compared to healthy subjects but
that TG are also stored in other organs called ectopic fat
depositions, for example, in the liver, skeletal muscle, heart,
and perhaps the pancreas [19, 116].
It has been proposed that genetic, environmental, and
behavioral factors determine the response of adipose tissue
to excess energy intake over energy expenditure. A phys-
iologic response to this would be adipocyte hyperplasia,
that is both an increase in adipocyte number with a
small increase in adipocyte size. A pathologic response
leads to adipocyte hypertrophy. Hypertrophic adipocytes
become stressed because of hypoxia and nutritional overload
of the endoplasmatic reticulum. Subsequently, stress and
inflammatory pathways are activated. The adipocytes secrete
cytokines and chemokines that interfere with the insulin
signaling pathway. In addition, macrophages are attracted
in the stromal vascular fraction of adipose tissue and
sustain a chronic inflammatory response. Insulin-resistant
hypertrophic adipocytes have increased lipolytic activity,
together with the impaired ability of to take up FFAs, and
consequently, a redirection of lipids towards nonadipose
tissues (ectopic fat deposition) ensues [10].
If fatty acid beta-oxidation in the mitochondria cannot
keep up with the increased supply of FFA to nonadipose
tissues such as the liver, skeletal muscle, pancreas, and heart,
accumulation of lipid intermediates like DAG and ceramides
occurs. These lipid intermediates lead to activation of ser-
ine/threonine kinases that phosphorylate IRS molecules on
serine residues. Serine phosphorylated IRS do not function
properly, hence insulin signaling is impaired, and normal
metabolic processes are disrupted.
Indeed, ectopic fat in the liver [67] and muscle [26]
is positively correlated with insulin resistance and T2DM.
Myocardial steatosis is associated with impaired diastolic
function [104], and fat around the heart is associated with
coronary artery disease [93] and related to whole-body
insulin resistance [90]. The consequences of elevated fatty
acids and/or lipid accumulation in the pancreas seem to be
only in order when elevated glucose levels are already present
[11].
The data in this paper show that substantial weight loss
mobilizes ectopic fat stores in all organs and that this is
associated with an improvement of the function of that
organ. Thus, a reduction in hepatic TG was accompanied
by a decline in fasting EGP [41, 73] and an improvement in
the insulin suppressibility of EGP. A decrease in myocardial
TG [112] and epicardial fat [97] were both associated with
improved diastolic cardiac function. Finally, a decline in
IMCLs leads to an improved insulin-stimulated glucose
disposal [50].
It should be noted, however, that the amount of weight
loss and/or the severity of caloric restriction are of influence
on this positive eﬀect and that there seems to be a tissue-
specific reaction. For example, around eight kilograms
weight loss following a 1200 kcal/day diet for 7 weeks led
to a decrease in hepatic TG and improved insulin sensitivity
of the liver but had no eﬀect on insulin-stimulated glucose
disposal or IMCLs in obese T2DMpatients [41].When obese
womenwith a history of gestational diabetes were subdivided
into groups with high and low liver fat, a similar weight
loss led to greater loss of hepatic fat in the high liver fat
group while both groups lost an equal amount of visceral and
subcutaneous fat [72]. A VLCD for 8 weeks in moderately
obese (BMI 33.6± 1.2 kg/m2) patients with T2DM < 4 years
duration decreased body weight by 15.3 ± 1.2 kg. Like the
study with 8 kg weight loss by hypocaloric diet, this decreased
IHL content and improved hepatic insulin sensitivity but had
no eﬀect on insulin-stimulated glucose disposal. Apparently,
either a longer duration of severe caloric restriction or a
greater weight loss is necessary to improve insulin-stimulated
glucose disposal. We showed that a prolonged VLCD inmore
severely obese insulin-dependent T2DM patients leading
to around 22 kg of weight reduction improved insulin-
stimulated glucose disposal and decreased IMCLs [50]. We
recently corroborated these findings in a similar group of
patients who underwent a 16-week VLCD (clamp data sub-
mitted for publication): ∼27 kg weight loss improved both
hepatic as well as peripheral insulin sensitivity. The largest
reduction occurred in hepatic TG content (−85%), whereas
IMCLs accumulation in the skeletal muscle decreased by
38%. The relative reduction in visceral fat was larger than the
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reduction in subcutaneous abdominal fat (−60% and −45%
resp.) (accepted for publication in Obesity [98]).
The above studies suggest that hepatic TG content is the
most easily mobilized, followed by visceral fat. The tissue-
specific reaction to dietary interventions is also present when,
vice versa, patients are subjected to high-fat feeding. Three
days of a high-fat high-energy diet in health young males
greatly increased hepatic TG stores but had no eﬀect on
myocardial TG [117].
Few studies have investigated the eﬀect of exercise per se,
that is, exercise without weight loss and/or caloric restriction.
The eﬀect of exercise varies in the diﬀerent organs with
respect to TG accumulation. In muscle, exercise can even
increase IMCLs [47, 55, 56]. However, when this is accom-
panied with increased fatty acid oxidation this is positive and
in accordance with the athlete’s paradox. The latter refers
to the fact that endurance-trained athletes have increased
IMCLs but are very insulin sensitive [26]. In these athletes the
IMCLs are a substrate source during exercise, and the high
turnover rate prevents accumulation of lipid intermediates
that have a negative eﬀect on insulin signaling and can form
lipid peroxides. In the sedentary state, when metabolic flex-
ibility is low, IMCLs accumulate with the afore-mentioned
deleterious eﬀect on cellular processes [27]. Exercise alone
can either increase [47, 55, 56] or decrease IMCLs [54]
but does improve insulin sensitivity (Table 1). Apart from
a decrease in lipid intermediates with increased fatty acid
oxidation, an increase in capillary density and activation of
AMPK with subsequently enhanced GLUT4 translocation
might also be involved in the observed improvement in
peripheral insulin sensitivity. Exercise in combination with
diet also depletes hepatic TG content and improves hepatic
insulin sensitivity [78], whereas it is undecided yet whether
exercise alone depletes hepatic TG content [80, 81]. The
underlying mechanism for depletion of IHL is probably not
direct but via a decrease in factors produced by adipose [9]
and skeletal muscle tissue. Exercise only reduces epicardial
fat, but cardiac function was not measured in that study [99].
Exercise improved left ventricular ejection fraction after a 12-
week exercise intervention in obese NGT and obese T2DM
subjects. However, myocardial TG content in the T2DM
patients were not aﬀected, suggesting that either a decrease in
myocardial TG content is not relevant for the improvement
in cardiac function, or that we might be looking to the same
paradox found in skeletal muscle (athletes paradox [26]).
Further research should focus both on the origins and
processes involved in adipose tissue dysfunction as well as
on the consequences of ectopic fat on the cellular level.
One of the key questions is whether the impaired fatty
acid oxidation is the cause or consequence of impaired
mitochondrial function. Recent evidence points to the latter
[38]. That might have consequences for therapy. In addition,
the role of the gut microbiota in inducing inflammation
and insulin resistance should be unraveled [118, 119].
Nevertheless, given the fact that subjects adopting a Western
diet rapidly become insulin resistant [120], and that this diet
both changes gut microbiota, inflammation, and adiposity
(vice versa weight loss and healthy diets change these
parameters for the better) strongly supports that excess
dietary fat induces an inflammatory response and impairs
mitochondrial function if lipid oxidation cannot keep up
with increased FFA delivery. Diet and exercise are powerful
tools in improving both ectopic fat deposition and the
function of the organ in which the ectopic fat is deposited.
Diet and lifestyle intervention, therefore, deserve more
attention, both as preventive measure for obesity and T2DM
as well as for the treatment of insulin resistance and T2DM.
When prescribing diet and exercise, it appears that
exercise only has little eﬀect on body weight and depletion
of intracellular lipid stores but does improve skeletal muscle
insulin sensitivity (most likely via increased contraction
mediated GLUT-4 translocation) and perhaps cardiac func-
tion. With respect to diets only, moderate caloric restriction
(>1200 kcal/day) and moderate weight loss (3–15 kg) only
improve hepatic insulin sensitivity. More severe energy
restriction (VLCD < 800 kcal/day) for a longer period (>8
weeks) and/or greater weight loss (>20 kg) are necessary to
improve insulin-stimulated peripheral glucose uptake.
Appendix
A. Literature Search Details
A.1. Pubmed. (“Diabetes Mellitus, Type 2” [Majr] OR
((diabetic [ti] OR “diabetes mellitus” [ti]) AND “type 2”
[ti]) OR “obesity” [Majr] OR “insulin resistance” [Majr] OR
“obesity” [ti] OR “insulin resistance” [ti] OR obese [ti] OR
“Non-Insulin-Dependent Diabetes Mellitus” [ti] OR “Type
2 Diabetes Mellitus” [ti] OR “Stable Diabetes Mellitus” [ti]
OR “Maturity-Onset Diabetes Mellitus” [ti] OR MODY [ti]
OR NIDDM [ti] OR “Adult-Onset Diabetes Mellitus” [ti])
AND “Weight Loss” [Mesh] OR “weight reduction” [tw]
OR “weight loss” [tw] OR “Diet” [mesh] OR diet [tw]
OR diets [tw] OR “Carbohydrate-Restricted” [tw] OR “Fat-
Restricted” [tw] OR “Caloric Restriction” [tw] OR “Caloric
Restrictions” [tw] OR “low carb” [tw] OR “low fat” [tw]
OR “low caloric” [tw] OR VLCD [tw] OR “low energy”
[tw] OR “low calorie” [tw] OR “Diet Therapy” [Mesh] OR
“Behavior Therapy” [Mesh] OR “behavior therapy” [tw]
OR “behaviour therapy” [tw] OR “conditioning therapy”
[tw] OR “behavior modification” [tw] OR “behavior mod-
ifications” [tw] OR “cognitive therapy” [tw] OR “behaviour
modification” [tw] OR “behaviour modifications” [tw] OR
“Exercise” [mesh] OR exercise [tw] OR “Sports” [Mesh]
OR sports [tw] OR sport [tw] AND (“ectopic fat” [tw] OR
“ectopic lipid” [tw] OR “ectopic lipids” [tw] OR “hepatic
steatosis” [tw] OR “fatty liver” [mesh] OR “fatty liver”
[tw] OR NAFLD [tw] OR NASH [tiab] OR “nonalcoholic
steatohepatitis” [tw] OR “nonalcoholic steatohepatitis” [tw]
OR “liver steatosis” [tw] OR “hepatic triglyceride” [tw] OR
“hepatic triglycerides” [tw] OR “liver triglyceride” [tw] OR
“hepatic triglycerides” [tw] OR “Myocardial triglyceride”
[tw] OR “Myocardial triglycerides” [tw] OR “Epicardial fat”
[tw] OR “pericardial fat” [tw] OR “mediastinal fat” [tw] OR
“intrathoracic fat” [tw] OR “intramyocellular triglyceride”
[tw] OR “intramyocellular triglycerides” [tw] OR “intramy-
ocellular lipid” [tw] OR “intramyocellular lipid” [tw] OR
“intramyocellular fat” [tw] OR IMCLs [tw]).
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A.2. EMBASE (OVID-Version). (∗non insulin dependent di-
abetes mellitus/OR ((diabetic OR “diabetes mellitus”) AND
“type 2”).ti OR exp ∗obesity/OR ∗insulin resistance/OR obe-
sity.ti OR insulin resistance.ti OR obese.ti OR Non-Insulin-
Dependent Diabetes Mellitus.ti OR “Type 2 Diabetes”.ti OR
“Stable Diabetes Mellitus”.ti OR “Maturity-Onset Diabetes
Mellitus”.ti OR MODY.ti OR NIDDM.ti OR “Adult-Onset
Diabetes Mellitus”.ti) AND (weight reduction/OR weight
reduction.mp OR weight loss.mp OR exp diet/OR diet.mp
OR diets.mp OR exp diet therapy/OR exp dietary intake/OR
Carbohydrate Restrict∗.mp OR Fat Restrict∗.mp OR Caloric
Restrict∗.mp OR low carb.mp OR low fat.mp OR low
caloric.mp OR VLCD.mp OR low energy.mp OR low
calorie.mp OR behavior therapy/OR behavior therapy.mp
OR behaviour therapy.mp OR conditioning therapy.mp
OR behavior modification/OR behavior modification∗.mp
OR cognitive therapy/OR psychotherapy/OR cognitive ther-
apy.mp OR behaviour modification∗.mp OR exp exer-
cise/OR exercise.mp OR exp Sport/OR exp physical activ-
ity/OR sports.mp OR sport.mp AND (ectopic fat∗.mp OR
ectopic lipid∗.mp OR exp fatty liver/OR hepatic steatosis.mp
OR fatty liver.mp OR NAFLD.mp OR NASH.mp OR non-
alcoholic steatohepatitis.mp OR nonalcoholic steatohepati-
tis.mp OR liver steatosis.mp OR hepatic triglycerid∗.mp
OR liver triglycerid∗ OR myocardial triglycerid∗.mp OR
epicardial fat.mp OR pericardial fat∗.mp OR mediastinal
fat∗.mp OR intrathoracic fat∗.mp OR intramyocellular
triglycerid∗.mp OR intramyocellular lipid∗.mp OR intramy-
ocellular fat∗.mp OR IMCLs.mp).
A.3. Web of Science. TI = (non insulin dependent diabetes
mellitus OR ((diabetic OR “diabetes mellitus”) AND “type
2”) OR obesity OR insulin resistance OR insulin resistance
OR obese OR Non-Insulin-Dependent Diabetes Mellitus
OR “Type 2 Diabetes” OR “Stable Diabetes Mellitus”
OR “Maturity-Onset Diabetes Mellitus” OR MODY OR
NIDDM OR “Adult-Onset Diabetes Mellitus”) AND TS =
(weight reduction OR weight loss OR diet OR diets OR
dietary intake OR Carbohydrate Restrict∗ OR Fat Restrict∗
OR Caloric Restrict∗ OR low carb OR low fat OR low
caloric OR VLCD OR low energy OR low calorie OR
behavior therapy OR behaviour therapy OR conditioning
therapy OR behavior modification∗ OR cognitive therapy
OR psychotherapy OR behaviour modification∗ OR exercise
OR physical activity OR sports OR sport) AND TS =
(“ectopic fat∗” OR “ectopic lipid∗” OR “fatty liver” OR
“hepatic steatosis” OR NAFLD OR NASH OR “nonalcoholic
steatohepatitis” OR “nonalcoholic steatohepatitis” OR “liver
steatosis” OR “hepatic triglycerid∗” OR “liver triglycerid∗”
OR “myocardial triglycerid∗” OR “epicardial fat” OR “peri-
cardial fat∗” OR “mediastinal fat∗” OR “intrathoracic fat∗”
OR “intramyocellular triglycerid∗” OR “intramyocellular
lipid∗” OR “intramyocellular fat∗” OR IMCLs).
A.4. Cochrane Library.
ID Search
#1 MeSH descriptor Diabetes Mellitus, Type 2
explode all trees
#2 MeSH descriptor Obesity explode all trees
#3 MeSH descriptor Insulin Resistance explode all
trees
#4 (diabet∗ AND “type 2”) OR obesity OR insulin
resistance OR obese OR “Non-Insulin-Dependent
Diabetes Mellitus” OR “Type 2 Diabetes Mellitus”
OR “Stable Diabetes Mellitus” OR “Maturity-Onset
Diabetes Mellitus” OR MODY OR NIDDM OR
“Adult-Onset Diabetes Mellitus”:ti
#5 (#1 OR #2 OR #3 OR #4)
#6 MeSH descriptor Weight Loss explode all trees
#7 MeSH descriptor Diet explode all trees
#8 MeSH descriptor Diet Therapy explode all trees
#9 MeSH descriptor Behavior Therapy explode all
trees
#10 MeSH descriptor Exercise explode all trees
#11 MeSH descriptor Sports explode all trees
#12 ((“anti obesity” OR “anti-obesity” OR antiobe-
sity OR “weight-loss” OR “weight loss”) AND
“weight reduction” OR “weight loss” OR diet
OR diets OR “Carbohydrate-Restricted” OR “Fat-
Restricted” OR “Caloric Restriction” OR “Caloric
Restrictions” OR “low carb” OR “low fat” OR “low
caloric” ORVLCDOR “low energy”OR “low calorie”
OR “behavior therapy” OR “behaviour therapy” OR
“conditioning therapy” OR “behavior modification”
OR “behavior modifications” OR “cognitive therapy”
OR “behaviour modification” OR “behaviour modi-
fications” OR exercise OR sports OR sport ∗:ti,ab,kw
#13 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14 MeSH descriptor Fatty Liver explode all trees
#15 (“ectopic fat” OR “ectopic lipid” OR “ectopic
lipids” OR “hepatic steatosis” OR “fatty liver” OR
NAFLD OR NASH OR “nonalcoholic steatohep-
atitis” OR “nonalcoholic steatohepatitis” OR “liver
steatosis” OR “hepatic triglyceride” OR “hepatic
triglycerides” OR “liver triglyceride” OR “hep-
atic triglycerides” OR “Myocardial triglyceride” OR
“Myocardial triglycerides” OR “Epicardial fat” OR
“pericardial fat” OR “mediastinal fat” OR “intratho-
racic fat” OR “intramyocellular triglyceride” OR
“intramyocellular triglycerides” OR “intramyocellu-
lar lipid” OR “intramyocellular lipid” OR “intramy-
ocellular fat” OR IMCLs): ti,ab,kw
#16 (#14 OR #15)
#17 (#5 AND #13 AND #16).
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Abbreviations
ALT: Alanine aminotransferase
AMPK: Activate adenosine
monophosphate-activated protein kinase
AST: Aspartate aminotransferase
BMI: Body mass index
CPT1: Carnitine-palmitoyl transferase 1
CR: Calorie restriction
CT: Computertomography
CVD: Cardiovascular disease
DAG: Diacylglycerol
EGP: Endogenous glucose production
ER: Endoplasmatic reticulum
FAT/CD36: Fatty acid transporter CD36
FATP: Fatty acid transport protein
FABP: Fatty acid binding protein
FFA: Free fatty acid
FOXO: Forkhead box protein O
GLUT4: Glucose transporter 4
IGT: Impaired glucose tolerant
IL: Interleukin
IHL: Intrahepatic lipids
IMCLs: Intramyocellular lipid content
IRS1: Insulin receptor substrate 1
1H-MRS: Proton magnetic resonance spectroscopy
HOMA-IR: Homeostatic model assessment of insulin
resistance
LC-CoA: Long-chain acyl-CoA
MRI: Magnetic resonance imaging
NAFLD: Nonalcoholic fatty liver disease
NASH: Nonalcoholic steatohepatitis
NGT: Normal glucose tolerant
PI3K: Phosphatidylinositol 3-kinase
PKB: Protein kinase B
PKC: Protein kinase C
T2DM: Type 2 diabetes mellitus
TNFα: Tumour necrosis factor alpha
TG: Triglyceride
UPR: Unfolded protein response
VLCD: Very low-calorie diet
VO2max: Maximum aerobic capacity.
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